Why Ciitizen is interesting

Ciitizen used HIPAA access rights to aggregate records for trials and research — a16z Bio led seed and Series A before Invitae's $325M acquisition.

Key facts

• Acquired by Invitae (Sep 2021): ~$325M cash and stock (PR Newswire, MedCity News)
• Series A (Jan 2019): $17M led by a16z Bio; Section 32, Verily participated (TechCrunch)
• Source: https://www.prnewswire.com/news-releases/invitae-to-acquire-ciitizen-to-strengthen-its-patient-consented-health-data-platform-to-improve-personal-outcomes-and-global-research-301369974.html

Investors in our directory

Funds linked from Ciitizen's profile — open a fund page for stage focus and related deal articles.

Related funding articles

Venture Capital Tracker pieces that cover Ciitizen's financing or category context.

• a16z Portfolio Companies on Fire in 2026: AI, American Dynamism & More